住友制药iPS细胞疗法在京都大学医院完成首例帕金森病患者移植
First patient undergoes pioneering stem-cell treatment for Parkinson's
住友制药的iPS细胞疗法在日本完成首例帕金森病患者脑内移植,该疗法已于3月获日本有条件批准。公司称首例移植10月在京都大学医院进行;此前临床试验中7名50至69岁患者脑两侧分别植入500万或1000万个细胞,随访两年未发现重大不良事件,4人症状改善。公司计划到2029年3月为20至30名患者实施移植,并正在美国开展临床试验,若未来七年安全性与有效性得到确认将在日本获得正式批准。
材料给出该iPS细胞疗法从有条件批准到首例移植的时间线,并列出试验中的细胞剂量与两年随访结果。
A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease, the Japanese drugmaker behind the treatment said on Friday, in a world first following its conditional approval in the country.
Sumitomo Pharma's treatment involves transplanting millions of induced pluripotent stem (iPS) cells, which have the potential to develop into any cell in the body, into a patient's brain.
Japanese regulators approved the therapy in March, following a successful clinical trial.
"The first transplant was performed at Kyoto University Hospital in October," the company said on Friday in an earnings press release, without giving further details.
Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties with movement.
Worldwide, more than 10 million people are estimated to have the illness, according to the Parkinson's Foundation.
Currently available therapies "improve symptoms without slowing or halting the disease progression," it says.
iPS cells are created by inducing mature, already specialized cells to return to a juvenile state.
Under Sumitomo Pharma's treatment, iPS cells from healthy donors are developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's.
During a clinical trial, seven patients aged between 50 and 69 each received implants of either 5 million or 10 million cells on both sides of the brain.
They were then monitored for two years, and no major adverse effects were found. Four patients showed improvements in symptoms.
Sumitomo Pharma said on Friday it plans to carry out transplants on 20 to 30 patients by March 2029. It is also carrying out a clinical trial in the United States.
The treatment will gain full approval in Japan if its safety and efficacy are confirmed over the next seven years, according to local media.
Friday's announcement comes a month after a hospital in Osaka carried out the world's first surgery using sheets of heart muscle iPS cells that can help form new blood vessels and restore heart function.
Japan also gave conditional approval to that therapy in March.
Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: First patient undergoes pioneering stem-cell treatment for Parkinson's (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-patient-stem-cell-treatment-parkinson.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com